CNS Pharmaceuticals

CNSP

Market cap $1.91M

Newly formed executive team initiates global search for differentiated therapeutic assets for neurology and oncology indications, two of biopharma's largest and fastest-growing markets Strategic transformation driven by a comprehensive data analysis will enable new executive team to leverage decades of experience in these therapeutic areas Company pivoting from a singular focus on glioblastoma and will explore out-licensing of legacy assets berubicin and TPI 287 HOUSTON, TX / ACCESS Newswire / March 11, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (the "Company"), a biotechnology company focused on building a pipeline of innovative therapies in high-value neurology and oncology markets, today announced that it has launched a new corporate growth strategy designed to build a high-value pipeline in neurology and oncology. The strategy is being led by the newly formed executive team with deep experience across neurology, oncology and rare disease drug development.

Dr. Kelley adds two decades of highly relevant drug development and regulatory strategy experience spanning oncology, rare diseases and CNS Newly formed executive team is committed to execution and company evolution focused on patient and stakeholder value HOUSTON, TX / ACCESS Newswire / March 2, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the appointment of Lynne Kelley, MD, FACS, as Chief Medical Officer. Dr. Kelley brings more than two decades of global leadership experience across clinical development, translational medicine and regulatory strategy in oncology, rare diseases, CNS and medical devices.

New Members of the Strengthened Leadership Team Add Decades of Operational Execution, Pipeline Optimization and Transactional Expertise to Support Company Growth and Value Creation HOUSTON, TX / ACCESS Newswire / February 17, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the Company's recently appointed President and Chief Executive officer, Rami Levin, in close alignment with the Board of Directors, has recruited key members to his new executive team. These new appointments, which will be effective March 2, 2026, will help drive the Company's evolution.

Newly Appointed President & Chief Executive Officer, Rami Levin, Discusses Plans for a New Era at CNS Pharmaceuticals Strategic Focus, Pipeline Optimization and Formalizing Roadmap for Near and Long-Term Value Creation HOUSTON, TX / ACCESS Newswire / January 27, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today issued a Letter to Shareholders from its newly appointed President and Chief Executive Officer, Rami Levin. Dear Fellow Shareholders, I am honored to write to you for the first time in my role as President and Chief Executive Officer of CNS Pharmaceuticals.

Industry veteran Rami Levin, MBA appointed as President & Chief Executive Officer HOUSTON, TX / ACCESS Newswire / December 17, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced John Climaco has stepped down as Chief Executive Officer of CNS Pharmaceuticals and Rami Levin, MBA, has been appointed as President & Chief Executive Officer. Mr. Levin brings nearly 30 years of global leadership experience across oncology, neurology, rare diseases, endocrinology, and cell and gene therapy, with a proven track record of scaling organizations, advancing late-stage clinical programs, and driving transformative value creation.

CNS Pharmaceuticals, Inc. ( CNSP ) Shareholder/Analyst Call November 17, 2025 12:00 PM EST Company Participants John Climaco - CEO, President & Director Christopher Downs - Chief Financial Officer Presentation John Climaco CEO, President & Director Welcome, everyone. The Annual Meeting of the Stockholders of CNS Pharmaceuticals, Inc. is hereby convened and called to order.

Cash expected to fund operations into the second half of 2026 Company focused on advancing next-generation anti-cancer therapies derived from well-established drug classes, now engineered to cross the blood-brain barrier, potentially enhancing efficacy for patients Lead program, TPI 287, progressing toward Phase 2 study for treatment of glioblastoma multiforme (GBM), one of the most aggressive types of brain cancer, with a median survival of only around 15 months from the time of diagnosis HOUSTON, TX / ACCESS Newswire / November 17, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the third quarter ended September 30, 2025 and provided a corporate update. "As we head into the final quarter of the year, our mission remains centered on delivering meaningful developments for patients battling brain and CNS cancers.

HOUSTON, TX / ACCESS Newswire / November 10, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that three abstracts have been selected for poster presentation at the 2025 SNO Annual Meeting being held November 19-23, 2025 in Honolulu, HI. Details of the poster presentations are as follows: Title: Activity of Berubicin against Pediatric Diffuse Midline Glioma (DMG) cells: Preliminary data and future possibilities Presenter: Sandra Silberman, MD, PhD, Chief Medical Officer of CNS Pharmaceuticals Abstract Code: EXTH-133 Date and Time: Friday, November 21, 2025 at 11:45 am - 1:05 pm HST Location: Hawaii Convention Center, Kamehameha Exhibit Hall II & III Title: TPI 287, which in combination with Bevacizumab (BEV) has shown activity in patients with glioblastoma (GBM) after prior therapy, will be evaluated in a Phase 2 trial as well as in other CNS diseases Presenter: Sandra Silberman, MD, PhD, Chief Medical Officer of CNS Pharmaceuticals Abstract Code: CTNI-70 Date and Time: Saturday, November 22, 2025 at 11:45 am - 1:05 pm HST Location: Hawaii Convention Center, Kamehameha Exhibit Hall II & III Title: Primary results of the randomized clinical trial of Berubicin vs Lomustine in patients with glioblastoma after failure of primary therapy: Data analysis and future possibilities Presenter: Sandra Silberman, MD, PhD, Chief Medical Officer of CNS Pharmaceuticals Abstract Code: CTNI-74 Date and Time: Saturday, November 22, 2025 at 11:30 am - 12:45 pm HST Location: Hawaii Convention Center, Kamehameha Exhibit Hall II & III For more information about the event, please visit the meeting website.

HOUSTON, TX / ACCESS Newswire / September 3, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it will present at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025 in New York, NY.

Strong cash position of $12.1 million expected to fund operations into the second half of 2026 Driving lead program, TPI 287, towards Phase 2 study for treatment of glioblastoma multiforme (GBM) HOUSTON, TX / ACCESS Newswire / August 15, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the second quarter ended June 30, 2025 and provided a corporate update. "Every decision we make is grounded in our science and driven by a sense of urgency and responsibility to the patients and families counting on us for better outcomes.